Compare CNTX & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTX | MRCC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.7M | 133.2M |
| IPO Year | 2021 | 2012 |
| Metric | CNTX | MRCC |
|---|---|---|
| Price | $1.56 | $6.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | $5.67 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.5M | 135.4K |
| Earning Date | 11-05-2025 | 02-27-2026 |
| Dividend Yield | N/A | ★ 11.46% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $43,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $5.86 |
| 52 Week High | $2.00 | $8.85 |
| Indicator | CNTX | MRCC |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | 51.66 |
| Support Level | $1.09 | $6.08 |
| Resistance Level | $1.79 | $6.80 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 51.89 | 68.66 |
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.